Promoter Durga Devi Nannapaneni sold 50,000 shares of Natco Pharma in an off-market transaction, decreasing her stake from 1.98% to 1.95%.
A vertically integrated pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. Natco Pharma operates across three core business segments: finished dosage formulations, active pharmaceutical ingredients, and contract manufacturing services. The company maintains a strong research and development focus to drive innovation and develop specialized therapeutic solutions across oncology, cardiovascular, gastroenterology, and other critical therapeutic domains.
